Halofuginone inhibits the establishment and progression of melanoma bone metastases

Patricia Juaŕez, Khalid S. Mohammad, Juan Juan Yin, Pierrick G.J. Fournier, Ryan C. McKenna, Holly W. Davis, Xiang H. Peng, Maria Niewolna, Delphine Javelaud, John M. Chirgwin, Alain Mauviel, Theresa A. Guise

Research output: Contribution to journalArticle

30 Scopus citations


TGF-β derived from bone fuels melanoma bone metastases by inducing tumor secretion of prometastatic factors that act on bone cells to change the skeletal microenvironment. Halofuginone is a plant alkaloid derivative that blocks TGF-β signaling with antiangiogenic and antiproliferative properties. Here, we show for the first time that halofuginone therapy decreases development and progression of bone metastasis caused by melanoma cells through the inhibition of TGF-β signaling. Halofuginone treatment of human melanoma cells inhibited cell proliferation, phosphorylation of SMAD proteins in response to TGF-β, and TGF-β-induced SMAD-driven transcription. In addition, halofuginone reduced expression of TGF-β target genes that enhance bone metastases, including PTHrP, CTGF, CXCR4, and IL11. Also, cell apoptosis was increased in response to halofuginone. In nude mice inoculated with 1205Lu melanoma cells, a preventive protocol with halofuginone inhibited bone metastasis. The beneficial effects of halofuginone treatment were comparable with those observed with other anti - TGF-β strategies, including systemic administration of SD208, a small-molecule inhibitor of TGF-β receptor I kinase, or forced overexpression of Smad7, a negative regulator of TGF-β signaling. Furthermore, mice with established bone metastases treated with halofuginone had significantly less osteolysis than mice receiving placebo assessed by radiography. Thus, halofuginone is also effective in reducing the progression of melanoma bone metastases. Moreover, halofuginone treatment reduced melanoma metastasis to the brain, showing the potential of this novel treatment against cancer metastasis.

Original languageEnglish (US)
Pages (from-to)6247-6256
Number of pages10
JournalCancer Research
Issue number23
StatePublished - Dec 1 2012

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Halofuginone inhibits the establishment and progression of melanoma bone metastases'. Together they form a unique fingerprint.

  • Cite this

    Juaŕez, P., Mohammad, K. S., Yin, J. J., Fournier, P. G. J., McKenna, R. C., Davis, H. W., Peng, X. H., Niewolna, M., Javelaud, D., Chirgwin, J. M., Mauviel, A., & Guise, T. A. (2012). Halofuginone inhibits the establishment and progression of melanoma bone metastases. Cancer Research, 72(23), 6247-6256. https://doi.org/10.1158/0008-5472.CAN-12-1444